nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—cardial valve—dilated cardiomyopathy	0.0646	0.534	CbGeAlD
Bexarotene—Pseudolymphoma—Lisinopril—dilated cardiomyopathy	0.022	0.0349	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.0175	0.0705	CbGpPWpGaD
Bexarotene—RXRB—myocardium—dilated cardiomyopathy	0.0174	0.144	CbGeAlD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.0164	0.0663	CbGpPWpGaD
Bexarotene—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.0155	0.0246	CcSEcCtD
Bexarotene—Breast enlargement—Spironolactone—dilated cardiomyopathy	0.0136	0.0216	CcSEcCtD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.0135	0.0542	CbGpPWpGaD
Bexarotene—RXRG—heart—dilated cardiomyopathy	0.0129	0.107	CbGeAlD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.0127	0.051	CbGpPWpGaD
Bexarotene—RXRB—heart—dilated cardiomyopathy	0.0122	0.1	CbGeAlD
Bexarotene—Pancreatitis acute—Furosemide—dilated cardiomyopathy	0.0104	0.0165	CcSEcCtD
Bexarotene—RXRB—cardiac atrium—dilated cardiomyopathy	0.0104	0.0859	CbGeAlD
Bexarotene—Breast pain—Spironolactone—dilated cardiomyopathy	0.0101	0.0161	CcSEcCtD
Bexarotene—RXRA—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHA—dilated cardiomyopathy	0.00894	0.036	CbGpPWpGaD
Bexarotene—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.0087	0.0138	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.00857	0.0345	CbGpPWpGaD
Bexarotene—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00813	0.0129	CcSEcCtD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00781	0.0315	CbGpPWpGaD
Bexarotene—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00758	0.012	CcSEcCtD
Bexarotene—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00735	0.0117	CcSEcCtD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00734	0.0296	CbGpPWpGaD
Bexarotene—Ear disorder—Lisinopril—dilated cardiomyopathy	0.00669	0.0106	CcSEcCtD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00659	0.0266	CbGpPWpGaD
Bexarotene—Lethargy—Spironolactone—dilated cardiomyopathy	0.00656	0.0104	CcSEcCtD
Bexarotene—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—NPPA—dilated cardiomyopathy	0.0065	0.0262	CbGpPWpGaD
Bexarotene—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00607	0.00963	CcSEcCtD
Bexarotene—Ataxia—Spironolactone—dilated cardiomyopathy	0.00604	0.00958	CcSEcCtD
Bexarotene—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00594	0.00942	CcSEcCtD
Bexarotene—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00575	0.00911	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00566	0.0228	CbGpPWpGaD
Bexarotene—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.0055	0.00872	CcSEcCtD
Bexarotene—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.00548	0.00869	CcSEcCtD
Bexarotene—Bone marrow depression—Lisinopril—dilated cardiomyopathy	0.00535	0.00849	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00532	0.0214	CbGpPWpGaD
Bexarotene—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00526	0.00834	CcSEcCtD
Bexarotene—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00519	0.00823	CcSEcCtD
Bexarotene—Gout—Furosemide—dilated cardiomyopathy	0.00516	0.00818	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00514	0.0207	CbGpPWpGaD
Bexarotene—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00511	0.00811	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.00503	0.0203	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00503	0.0203	CbGpPWpGaD
Bexarotene—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00501	0.00795	CcSEcCtD
Bexarotene—RXRG—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00501	0.0202	CbGpPWpGaD
Bexarotene—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.0049	0.00777	CcSEcCtD
Bexarotene—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00488	0.00774	CcSEcCtD
Bexarotene—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.0048	0.00761	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.00473	0.0191	CbGpPWpGaD
Bexarotene—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00472	0.00748	CcSEcCtD
Bexarotene—RXRB—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00471	0.019	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.00455	0.0183	CbGpPWpGaD
Bexarotene—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00442	0.00701	CcSEcCtD
Bexarotene—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00436	0.00691	CcSEcCtD
Bexarotene—Urine output increased—Furosemide—dilated cardiomyopathy	0.00435	0.0069	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.00428	0.0172	CbGpPWpGaD
Bexarotene—Mental disability—Furosemide—dilated cardiomyopathy	0.00418	0.00663	CcSEcCtD
Bexarotene—Breast pain—Lisinopril—dilated cardiomyopathy	0.00414	0.00657	CcSEcCtD
Bexarotene—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.00411	0.00652	CcSEcCtD
Bexarotene—Viral infection—Lisinopril—dilated cardiomyopathy	0.004	0.00634	CcSEcCtD
Bexarotene—Polyuria—Furosemide—dilated cardiomyopathy	0.00398	0.00631	CcSEcCtD
Bexarotene—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00397	0.0063	CcSEcCtD
Bexarotene—Cough increased—Lisinopril—dilated cardiomyopathy	0.00395	0.00626	CcSEcCtD
Bexarotene—Alopecia—Spironolactone—dilated cardiomyopathy	0.00393	0.00623	CcSEcCtD
Bexarotene—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00391	0.0062	CcSEcCtD
Bexarotene—Deafness—Furosemide—dilated cardiomyopathy	0.00391	0.0062	CcSEcCtD
Bexarotene—Gout—Lisinopril—dilated cardiomyopathy	0.00387	0.00613	CcSEcCtD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00383	0.0154	CbGpPWpGaD
Bexarotene—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.0038	0.00602	CcSEcCtD
Bexarotene—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00372	0.0059	CcSEcCtD
Bexarotene—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.0037	0.00587	CcSEcCtD
Bexarotene—Thirst—Furosemide—dilated cardiomyopathy	0.00367	0.00582	CcSEcCtD
Bexarotene—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00366	0.0058	CcSEcCtD
Bexarotene—Purpura—Furosemide—dilated cardiomyopathy	0.00363	0.00575	CcSEcCtD
Bexarotene—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00359	0.00569	CcSEcCtD
Bexarotene—CYP2C9—heart—dilated cardiomyopathy	0.00357	0.0295	CbGeAlD
Bexarotene—Lethargy—Furosemide—dilated cardiomyopathy	0.00357	0.00566	CcSEcCtD
Bexarotene—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00355	0.00563	CcSEcCtD
Bexarotene—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00351	0.00556	CcSEcCtD
Bexarotene—Malaise—Spironolactone—dilated cardiomyopathy	0.00349	0.00553	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00347	0.014	CbGpPWpGaD
Bexarotene—RXRA—The citric acid (TCA) cycle and respiratory electron transport—SDHA—dilated cardiomyopathy	0.00347	0.014	CbGpPWpGaD
Bexarotene—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00346	0.00549	CcSEcCtD
Bexarotene—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00343	0.00544	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—LMNA—dilated cardiomyopathy	0.0034	0.0137	CbGpPWpGaD
Bexarotene—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00339	0.00538	CcSEcCtD
Bexarotene—Urinary retention—Furosemide—dilated cardiomyopathy	0.00332	0.00527	CcSEcCtD
Bexarotene—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00327	0.00519	CcSEcCtD
Bexarotene—Discomfort—Spironolactone—dilated cardiomyopathy	0.00325	0.00516	CcSEcCtD
Bexarotene—Dehydration—Furosemide—dilated cardiomyopathy	0.00325	0.00515	CcSEcCtD
Bexarotene—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00322	0.0051	CcSEcCtD
Bexarotene—Confusional state—Spironolactone—dilated cardiomyopathy	0.00318	0.00505	CcSEcCtD
Bexarotene—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00318	0.00504	CcSEcCtD
Bexarotene—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00317	0.00502	CcSEcCtD
Bexarotene—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00309	0.0049	CcSEcCtD
Bexarotene—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00308	0.00489	CcSEcCtD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.00305	0.0123	CbGpPWpGaD
Bexarotene—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00304	0.00482	CcSEcCtD
Bexarotene—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00299	0.00474	CcSEcCtD
Bexarotene—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00296	0.0047	CcSEcCtD
Bexarotene—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00296	0.00469	CcSEcCtD
Bexarotene—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00292	0.00463	CcSEcCtD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.00287	0.0116	CbGpPWpGaD
Bexarotene—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00283	0.00448	CcSEcCtD
Bexarotene—Somnolence—Spironolactone—dilated cardiomyopathy	0.00281	0.00445	CcSEcCtD
Bexarotene—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00279	0.00442	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00277	0.0112	CbGpPWpGaD
Bexarotene—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00276	0.00437	CcSEcCtD
Bexarotene—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00276	0.00437	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00273	0.00432	CcSEcCtD
Bexarotene—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00273	0.00432	CcSEcCtD
Bexarotene—Arthritis—Lisinopril—dilated cardiomyopathy	0.0027	0.00428	CcSEcCtD
Bexarotene—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00268	0.00424	CcSEcCtD
Bexarotene—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00263	0.00417	CcSEcCtD
Bexarotene—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00262	0.00416	CcSEcCtD
Bexarotene—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0026	0.00413	CcSEcCtD
Bexarotene—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.0026	0.00413	CcSEcCtD
Bexarotene—Sweating—Furosemide—dilated cardiomyopathy	0.00258	0.00409	CcSEcCtD
Bexarotene—Face oedema—Lisinopril—dilated cardiomyopathy	0.00253	0.00401	CcSEcCtD
Bexarotene—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.0025	0.00396	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.00247	0.00994	CbGpPWpGaD
Bexarotene—Ataxia—Lisinopril—dilated cardiomyopathy	0.00247	0.00391	CcSEcCtD
Bexarotene—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00246	0.0039	CcSEcCtD
Bexarotene—RXRA—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00245	0.00989	CbGpPWpGaD
Bexarotene—Dehydration—Lisinopril—dilated cardiomyopathy	0.00244	0.00387	CcSEcCtD
Bexarotene—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00239	0.00379	CcSEcCtD
Bexarotene—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00237	0.00376	CcSEcCtD
Bexarotene—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00233	0.00369	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00232	0.00937	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00229	0.00924	CbGpPWpGaD
Bexarotene—Influenza—Lisinopril—dilated cardiomyopathy	0.00227	0.00359	CcSEcCtD
Bexarotene—Eye disorder—Furosemide—dilated cardiomyopathy	0.00226	0.00358	CcSEcCtD
Bexarotene—Tinnitus—Furosemide—dilated cardiomyopathy	0.00225	0.00357	CcSEcCtD
Bexarotene—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00224	0.00356	CcSEcCtD
Bexarotene—Pruritus—Spironolactone—dilated cardiomyopathy	0.00223	0.00354	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.00223	0.00898	CbGpPWpGaD
Bexarotene—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00222	0.00352	CcSEcCtD
Bexarotene—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00221	0.0035	CcSEcCtD
Bexarotene—Angiopathy—Furosemide—dilated cardiomyopathy	0.00219	0.00348	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00219	0.00881	CbGpPWpGaD
Bexarotene—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00218	0.00346	CcSEcCtD
Bexarotene—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00216	0.00343	CcSEcCtD
Bexarotene—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00216	0.00343	CcSEcCtD
Bexarotene—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00215	0.00341	CcSEcCtD
Bexarotene—Dysuria—Lisinopril—dilated cardiomyopathy	0.00212	0.00336	CcSEcCtD
Bexarotene—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00212	0.00336	CcSEcCtD
Bexarotene—Malnutrition—Furosemide—dilated cardiomyopathy	0.00211	0.00334	CcSEcCtD
Bexarotene—Erythema—Furosemide—dilated cardiomyopathy	0.00211	0.00334	CcSEcCtD
Bexarotene—Dizziness—Spironolactone—dilated cardiomyopathy	0.00209	0.00331	CcSEcCtD
Bexarotene—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00209	0.00331	CcSEcCtD
Bexarotene—Flatulence—Furosemide—dilated cardiomyopathy	0.00207	0.00329	CcSEcCtD
Bexarotene—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00207	0.00328	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.00207	0.00834	CbGpPWpGaD
Bexarotene—Weight increased—Lisinopril—dilated cardiomyopathy	0.00206	0.00327	CcSEcCtD
Bexarotene—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00206	0.00327	CcSEcCtD
Bexarotene—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00205	0.00325	CcSEcCtD
Bexarotene—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00204	0.00324	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00204	0.00822	CbGpPWpGaD
Bexarotene—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00203	0.00322	CcSEcCtD
Bexarotene—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00202	0.00321	CcSEcCtD
Bexarotene—Vomiting—Spironolactone—dilated cardiomyopathy	0.00201	0.00318	CcSEcCtD
Bexarotene—Rash—Spironolactone—dilated cardiomyopathy	0.00199	0.00316	CcSEcCtD
Bexarotene—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00199	0.00315	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—FAS—dilated cardiomyopathy	0.00199	0.008	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00198	0.00314	CcSEcCtD
Bexarotene—Headache—Spironolactone—dilated cardiomyopathy	0.00198	0.00314	CcSEcCtD
Bexarotene—Jaundice—Lisinopril—dilated cardiomyopathy	0.00197	0.00312	CcSEcCtD
Bexarotene—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00196	0.00311	CcSEcCtD
Bexarotene—Anaemia—Furosemide—dilated cardiomyopathy	0.00195	0.00308	CcSEcCtD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.00194	0.00784	CbGpPWpGaD
Bexarotene—Sweating—Lisinopril—dilated cardiomyopathy	0.00194	0.00307	CcSEcCtD
Bexarotene—Agitation—Furosemide—dilated cardiomyopathy	0.00193	0.00307	CcSEcCtD
Bexarotene—Haematuria—Lisinopril—dilated cardiomyopathy	0.00193	0.00306	CcSEcCtD
Bexarotene—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00191	0.00302	CcSEcCtD
Bexarotene—Sinusitis—Lisinopril—dilated cardiomyopathy	0.0019	0.00301	CcSEcCtD
Bexarotene—Vertigo—Furosemide—dilated cardiomyopathy	0.00189	0.003	CcSEcCtD
Bexarotene—Leukopenia—Furosemide—dilated cardiomyopathy	0.00188	0.00299	CcSEcCtD
Bexarotene—Nausea—Spironolactone—dilated cardiomyopathy	0.00188	0.00297	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—AGT—dilated cardiomyopathy	0.00186	0.0075	CbGpPWpGaD
Bexarotene—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00182	0.00288	CcSEcCtD
Bexarotene—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.0018	0.00286	CcSEcCtD
Bexarotene—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00179	0.00284	CcSEcCtD
Bexarotene—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00179	0.00283	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00178	0.00282	CcSEcCtD
Bexarotene—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00178	0.00282	CcSEcCtD
Bexarotene—Dry mouth—Furosemide—dilated cardiomyopathy	0.00175	0.00278	CcSEcCtD
Bexarotene—Confusional state—Furosemide—dilated cardiomyopathy	0.00173	0.00275	CcSEcCtD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—TNF—dilated cardiomyopathy	0.00171	0.0069	CbGpPWpGaD
Bexarotene—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00169	0.00268	CcSEcCtD
Bexarotene—Shock—Furosemide—dilated cardiomyopathy	0.00169	0.00268	CcSEcCtD
Bexarotene—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00168	0.00267	CcSEcCtD
Bexarotene—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00168	0.00267	CcSEcCtD
Bexarotene—Skin disorder—Furosemide—dilated cardiomyopathy	0.00167	0.00265	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—LMNA—dilated cardiomyopathy	0.00167	0.00671	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00166	0.00263	CcSEcCtD
Bexarotene—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00165	0.00261	CcSEcCtD
Bexarotene—Anorexia—Furosemide—dilated cardiomyopathy	0.00164	0.0026	CcSEcCtD
Bexarotene—Chills—Lisinopril—dilated cardiomyopathy	0.00163	0.00258	CcSEcCtD
Bexarotene—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00162	0.00257	CcSEcCtD
Bexarotene—Alopecia—Lisinopril—dilated cardiomyopathy	0.0016	0.00254	CcSEcCtD
Bexarotene—Erythema—Lisinopril—dilated cardiomyopathy	0.00158	0.0025	CcSEcCtD
Bexarotene—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00158	0.0025	CcSEcCtD
Bexarotene—Flatulence—Lisinopril—dilated cardiomyopathy	0.00156	0.00247	CcSEcCtD
Bexarotene—Tension—Lisinopril—dilated cardiomyopathy	0.00155	0.00246	CcSEcCtD
Bexarotene—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00155	0.00245	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00155	0.00623	CbGpPWpGaD
Bexarotene—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00154	0.00245	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—CD36—dilated cardiomyopathy	0.00154	0.0062	CbGpPWpGaD
Bexarotene—Nervousness—Lisinopril—dilated cardiomyopathy	0.00153	0.00243	CcSEcCtD
Bexarotene—Back pain—Lisinopril—dilated cardiomyopathy	0.00153	0.00242	CcSEcCtD
Bexarotene—Somnolence—Furosemide—dilated cardiomyopathy	0.00153	0.00242	CcSEcCtD
Bexarotene—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00152	0.00241	CcSEcCtD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.0015	0.00603	CbGpPWpGaD
Bexarotene—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00149	0.00237	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00148	0.00235	CcSEcCtD
Bexarotene—Fatigue—Furosemide—dilated cardiomyopathy	0.00148	0.00235	CcSEcCtD
Bexarotene—Pain—Furosemide—dilated cardiomyopathy	0.00147	0.00233	CcSEcCtD
Bexarotene—Constipation—Furosemide—dilated cardiomyopathy	0.00147	0.00233	CcSEcCtD
Bexarotene—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00147	0.00232	CcSEcCtD
Bexarotene—Anaemia—Lisinopril—dilated cardiomyopathy	0.00146	0.00231	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.00146	0.00588	CbGpPWpGaD
Bexarotene—Malaise—Lisinopril—dilated cardiomyopathy	0.00142	0.00226	CcSEcCtD
Bexarotene—Vertigo—Lisinopril—dilated cardiomyopathy	0.00142	0.00225	CcSEcCtD
Bexarotene—Syncope—Lisinopril—dilated cardiomyopathy	0.00142	0.00225	CcSEcCtD
Bexarotene—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00142	0.00224	CcSEcCtD
Bexarotene—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00141	0.00224	CcSEcCtD
Bexarotene—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.0014	0.00223	CcSEcCtD
Bexarotene—Palpitations—Lisinopril—dilated cardiomyopathy	0.0014	0.00221	CcSEcCtD
Bexarotene—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00139	0.0022	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00138	0.00557	CbGpPWpGaD
Bexarotene—Cough—Lisinopril—dilated cardiomyopathy	0.00138	0.00219	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.00137	0.00553	CbGpPWpGaD
Bexarotene—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00136	0.00215	CcSEcCtD
Bexarotene—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00136	0.00215	CcSEcCtD
Bexarotene—Chest pain—Lisinopril—dilated cardiomyopathy	0.00134	0.00213	CcSEcCtD
Bexarotene—Myalgia—Lisinopril—dilated cardiomyopathy	0.00134	0.00213	CcSEcCtD
Bexarotene—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00134	0.00213	CcSEcCtD
Bexarotene—Anxiety—Lisinopril—dilated cardiomyopathy	0.00134	0.00212	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00134	0.00212	CcSEcCtD
Bexarotene—Discomfort—Lisinopril—dilated cardiomyopathy	0.00133	0.00211	CcSEcCtD
Bexarotene—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00132	0.00209	CcSEcCtD
Bexarotene—Confusional state—Lisinopril—dilated cardiomyopathy	0.0013	0.00206	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.0013	0.00523	CbGpPWpGaD
Bexarotene—Oedema—Lisinopril—dilated cardiomyopathy	0.00129	0.00204	CcSEcCtD
Bexarotene—Infection—Lisinopril—dilated cardiomyopathy	0.00128	0.00203	CcSEcCtD
Bexarotene—Shock—Lisinopril—dilated cardiomyopathy	0.00127	0.00201	CcSEcCtD
Bexarotene—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00127	0.00201	CcSEcCtD
Bexarotene—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00126	0.002	CcSEcCtD
Bexarotene—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00126	0.00199	CcSEcCtD
Bexarotene—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00125	0.00199	CcSEcCtD
Bexarotene—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00125	0.00198	CcSEcCtD
Bexarotene—Asthenia—Furosemide—dilated cardiomyopathy	0.00123	0.00195	CcSEcCtD
Bexarotene—Anorexia—Lisinopril—dilated cardiomyopathy	0.00123	0.00195	CcSEcCtD
Bexarotene—Pruritus—Furosemide—dilated cardiomyopathy	0.00122	0.00193	CcSEcCtD
Bexarotene—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00118	0.00186	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00117	0.00186	CcSEcCtD
Bexarotene—Insomnia—Lisinopril—dilated cardiomyopathy	0.00117	0.00185	CcSEcCtD
Bexarotene—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00116	0.00184	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.00116	0.00466	CbGpPWpGaD
Bexarotene—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00115	0.00182	CcSEcCtD
Bexarotene—Somnolence—Lisinopril—dilated cardiomyopathy	0.00115	0.00182	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00114	0.00459	CbGpPWpGaD
Bexarotene—Dizziness—Furosemide—dilated cardiomyopathy	0.00114	0.0018	CcSEcCtD
Bexarotene—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00113	0.0018	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.00113	0.00456	CbGpPWpGaD
Bexarotene—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00112	0.00178	CcSEcCtD
Bexarotene—RXRG—Gene Expression—NR3C2—dilated cardiomyopathy	0.00112	0.00451	CbGpPWpGaD
Bexarotene—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00111	0.00176	CcSEcCtD
Bexarotene—Fatigue—Lisinopril—dilated cardiomyopathy	0.00111	0.00176	CcSEcCtD
Bexarotene—Pain—Lisinopril—dilated cardiomyopathy	0.0011	0.00175	CcSEcCtD
Bexarotene—Constipation—Lisinopril—dilated cardiomyopathy	0.0011	0.00175	CcSEcCtD
Bexarotene—Vomiting—Furosemide—dilated cardiomyopathy	0.00109	0.00173	CcSEcCtD
Bexarotene—Rash—Furosemide—dilated cardiomyopathy	0.00108	0.00172	CcSEcCtD
Bexarotene—Dermatitis—Furosemide—dilated cardiomyopathy	0.00108	0.00172	CcSEcCtD
Bexarotene—Headache—Furosemide—dilated cardiomyopathy	0.00108	0.00171	CcSEcCtD
Bexarotene—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00106	0.00168	CcSEcCtD
Bexarotene—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00105	0.00167	CcSEcCtD
Bexarotene—RXRB—Gene Expression—NR3C2—dilated cardiomyopathy	0.00105	0.00424	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.00104	0.0042	CbGpPWpGaD
Bexarotene—Nausea—Furosemide—dilated cardiomyopathy	0.00102	0.00162	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.00102	0.00411	CbGpPWpGaD
Bexarotene—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00102	0.00162	CcSEcCtD
Bexarotene—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00102	0.00162	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.00101	0.00408	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—FAS—dilated cardiomyopathy	0.000973	0.00392	CbGpPWpGaD
Bexarotene—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00095	0.00151	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000936	0.00377	CbGpPWpGaD
Bexarotene—Asthenia—Lisinopril—dilated cardiomyopathy	0.000925	0.00147	CcSEcCtD
Bexarotene—Pruritus—Lisinopril—dilated cardiomyopathy	0.000912	0.00145	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—AGT—dilated cardiomyopathy	0.000911	0.00367	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00091	0.00367	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00091	0.00367	CbGpPWpGaD
Bexarotene—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000882	0.0014	CcSEcCtD
Bexarotene—Dizziness—Lisinopril—dilated cardiomyopathy	0.000852	0.00135	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000846	0.00341	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—TNF—dilated cardiomyopathy	0.000843	0.0034	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000833	0.00336	CbGpPWpGaD
Bexarotene—Vomiting—Lisinopril—dilated cardiomyopathy	0.00082	0.0013	CcSEcCtD
Bexarotene—Rash—Lisinopril—dilated cardiomyopathy	0.000813	0.00129	CcSEcCtD
Bexarotene—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000812	0.00129	CcSEcCtD
Bexarotene—Headache—Lisinopril—dilated cardiomyopathy	0.000808	0.00128	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.00078	0.00314	CbGpPWpGaD
Bexarotene—Nausea—Lisinopril—dilated cardiomyopathy	0.000766	0.00121	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000742	0.00299	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000715	0.00288	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000715	0.00288	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NPPA—dilated cardiomyopathy	0.000703	0.00283	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000702	0.00283	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000701	0.00283	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NPPA—dilated cardiomyopathy	0.000661	0.00266	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000652	0.00263	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—dilated cardiomyopathy	0.000628	0.00253	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ANKRD1—dilated cardiomyopathy	0.000615	0.00248	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TAZ—dilated cardiomyopathy	0.000578	0.00233	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NR3C2—dilated cardiomyopathy	0.000548	0.00221	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—SDHA—dilated cardiomyopathy	0.000523	0.00211	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000516	0.00208	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000485	0.00195	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000465	0.00187	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—TNF—dilated cardiomyopathy	0.000413	0.00166	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000408	0.00164	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CD36—dilated cardiomyopathy	0.000348	0.0014	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NPPA—dilated cardiomyopathy	0.000344	0.00139	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—RAC1—dilated cardiomyopathy	0.000328	0.00132	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000319	0.00129	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000319	0.00128	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000311	0.00125	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000304	0.00122	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.00028	0.00113	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.00023	0.000926	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—RAF1—dilated cardiomyopathy	0.000217	0.000876	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000216	0.00087	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.000195	0.000787	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000185	0.000744	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000151	0.00061	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—dilated cardiomyopathy	0.000149	0.000601	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000142	0.000574	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GPX1—dilated cardiomyopathy	0.000142	0.000573	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TNF—dilated cardiomyopathy	0.000142	0.000572	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CD36—dilated cardiomyopathy	0.000138	0.000558	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000129	0.000519	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AGT—dilated cardiomyopathy	0.000125	0.000502	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000119	0.00048	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000116	0.000467	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000104	0.000421	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	5.3e-05	0.000214	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	5.17e-05	0.000208	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.65e-05	0.000187	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.5e-05	0.000141	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.41e-05	0.000137	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	3.07e-05	0.000124	CbGpPWpGaD
